Skip to main content

Treatment Clinical Trials for Myelodysplastic Syndrome

Review the myelodysplastic syndrome treatment clinical trials on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 126-150 of 217

Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferative Neoplasm with FLT3 or CBL Mutations
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Decitabine and Venetoclax in Combination with Olutasidenib for the Treatment of Patients with Newly Diagnosed, Recurrent or Refractory Acute Myeloid Leukemia
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Venetoclax with Combination Chemotherapy in Treating Patients with Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Clinical Study of ARD103 CAR-T Therapy for Patients With R/R AML or MDS
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Nadunolimab and Azacitidine With or Without Venetoclax for the Treatment of Patients with Myelodysplastic Syndrome or Relapsed or Refractory Acute Myelogenous Leukemia
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Quizartinib, Decitabine, and Venetoclax in Treating Patients with Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
ONC201 Alone or in Combination with Venetoclax in Treating Patients with Relapsed or Refractory Acute Leukemia or High-Risk Myelodysplastic Syndrome
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients with Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
211^At-BC8-B10 before Donor Stem Cell Transplant in Treating Patients with High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia
Status: Active
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
PRAME-TCR-NK Cells with Lymphodepleting Chemotherapy for the Treatment of Relapsed and Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome/Chronic Myelomonocytic Leukemia
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
211At-BC8-B10 followed by Donor Stem Cell Transplant in Treating Patients with Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome
Status: Active
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
Genetically Engineered Cells (TGFBR2 KO CAR27/IL-15 NK cells) for the Treatment of Relapsed or Refractory Myeloid Malignancies
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
αβT Cell/CD19+ B Cell Depletion for Alternative Donor Stem Cell Transplant for Children and Young Adults with Hematologic Malignancies
Status: Active
Location: Nationwide Children's Hospital, Columbus, Ohio
Chemotherapy (Decitabine in Combination with FLAG-Ida) and Total-Body Irradiation followed by Donor Stem Cell Transplant for the Treatment of Adults with Myeloid Malignancies at High Risk of Relapse
Status: Active
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ...
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Venetoclax Combined with Intensive Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia or Intermediate and Higher Risk Myelodysplastic Syndrome
Status: Active
Location: Montefiore Medical Center-Weiler Hospital, Bronx, New York
Tagraxofusp and Azacitidine for Maintenance Treatment in Patients with CD123 Positive AML and MDS Following Donor Hematopoietic Cell Transplant
Status: Active
Location: City of Hope Comprehensive Cancer Center, Duarte, California
Olutasidenib for the Treatment of Patients with IDH1 Mutated AML, MDS or CMML after Donor Hematopoietic Cell Transplant
Status: Active
Location: City of Hope Comprehensive Cancer Center, Duarte, California
Ziftomenib for the Treatment of Patients with Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, and Myelodysplastic Syndrome Following Donor Hematopoietic Cell Transplant
Status: Active
Location: Massachusetts General Hospital Cancer Center, Boston, Massachusetts
Orca-T following Chemotherapy and Total Marrow and Lymphoid Irradiation for the Treatment of Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia or Myelodysplastic Syndrome
Status: Active
Location: City of Hope Comprehensive Cancer Center, Duarte, California
Iadademstat in Combination with Azacitidine and Venetoclax in Treating Newly Diagnosed Acute Myeloid Leukemia
Status: Active
Location: OHSU Knight Cancer Institute, Portland, Oregon
Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Renal Impairment
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas